Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
- Altimmune will present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking poster presentation at The Liver Meeting® 2023. The data shows that pemvidutide-induced liver fat reduction in subjects with NAFLD correlates with improvements in non-invasive markers of inflammation and fibrosis.
- None.
GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023). Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
Details for the presentation are as follows:
| Title: | Pemvidutide-induced liver fat reduction in subjects with non-alcoholic fatty liver disease correlate with improvements in non-invasive markers of inflammation and fibrosis: Results of a 24-week multicenter, randomized, double-blind, placebo-controlled trial |
| Presenter: | Dr. Stephen Harrison, Medical Director, Pinnacle Research, and Adjunct Professor of Medicine, Oxford University |
| Date/Time: | Late Breaking Poster Session, Monday, November 13, 2023, at 1:00 pm EST |
The late-breaking poster will be made available on the Events section of the Altimmune website at the time of the presentation.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, leading to rapid reductions in levels of liver fat. Pemvidutide incorporates the EuPort™ domain, a proprietary technology that increases its serum half-life for weekly dosing while likely slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Media Contact:
Danielle Cantey
Evoke Canale
Phone: 619-826-4657
danielle.cantey@evokegroup.com
FAQ
When will Altimmune present the new data on pemvidutide?
What are the properties of pemvidutide?
What does the data show about pemvidutide in NAFLD?
